New shot could tame rare bleeding disorder
NCT ID NCT07347249
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This study tests a new drug called sutacimig in 18 adults with a rare inherited bleeding disorder (factor VII deficiency). The drug is given as a single shot under the skin to see if it is safe and can help prevent bleeding. The goal is to find a more convenient treatment option for people who currently need frequent infusions.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sutacimig (a bispecific antibody given as a shot under the skin)
What this could lead to
If it works, this could point toward a new preventive treatment to reduce bleeding episodes in people with factor VII deficiency.
What could go wrong
This is a very early, small Phase 2 trial with only 18 people, so results may not apply to everyone. The drug is still experimental, and safety or effectiveness is not yet proven.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CONGENITAL FACTOR VII DEFICIENCY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Royal London Hospital
RECRUITINGLondon, E1 2ES, United Kingdom
Contact Phone: •••-•••-•••• Email: •••••@•••••